MetaCap

AgomAb Therapeutics NV (AGMB) vs X4 Pharmaceuticals (XFOR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

X4 Pharmaceuticals is the larger company by market cap ($306.3 million vs $268.4 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AGMB-62.80%XFOR-15.73%
+36%-16%-67%
Feb 6, 20261 yearNov 20, 2026
AGMB-62.80%XFOR-15.73%
+35%-16%-67%
Feb 2, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AGMB versus XFOR key metrics
MetricAGMBXFOR
Share price$5.45$3.00
Market cap$268.40M$306.34M
1-day change-3.02%+1.35%
YTD return—-25.00%
1-year return—-20.00%
5-year return—-97.79%
P/E ratio (TTM)—5.45
EPS (TTM)$-2.08$0.55
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$6.50M
Revenue growth (YoY)—+150.00%
Net income (latest FY)—$-79.20M
Gross margin—11.43%
Operating margin—-1336.66%
Net margin—-1218.45%
52-week high$17.82$4.83
52-week low$5.39$2.43
Distance from 52-week high-69.42%-37.89%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+591.19%+286.67%
Average volume208.99K877.70K
Shares outstanding49.25M102.11M
Employees6245
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About AgomAb Therapeutics NV

AGMB stock →

AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 62 employees

About X4 Pharmaceuticals

XFOR stock →

X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 45 employees

AGMB vs XFOR FAQ

Which is bigger, AgomAb Therapeutics NV or X4 Pharmaceuticals?

X4 Pharmaceuticals (XFOR) is larger, with a market capitalization of $306.34M compared with $268.40M for AgomAb Therapeutics NV (AGMB).

Are AgomAb Therapeutics NV and X4 Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons